Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Piot, R. Feachem, Jong-wook Lee, J. Wolfensohn (2004)
A Global Response to AIDS: Lessons Learned, Next StepsScience, 304
K. Wolf, James Young, M. Rickenbach, P. Vernazza, M. Flepp, H. Furrer, E. Bernasconi, B. Hirschel, A. Telenti, R. Weber, H. Bucher (2003)
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study.Journal of acquired immune deficiency syndromes, 33 4
Jon Cohen (2005)
AIDS treatment. A step toward cheaper anti-HIV therapy.Science, 307 5710
R. Nuesch, P. Srasuebkul, J. Ananworanich, K. Ruxrungtham, P. Phanuphak, C. Duncombe (2006)
Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.The Journal of antimicrobial chemotherapy, 58 3
G. Touloumi, N. Pantazis, A. Antoniou, H. Stirnadel, S. Walker, K. Porter (2006)
Highly Active Antiretroviral Therapy Interruption: Predictors and Virological and Immunologic ConsequencesJAIDS Journal of Acquired Immune Deficiency Syndromes, 42
A large and well designed randomized controlled trial on CD4 cell count-guided treatment interruption performed exclusively in Africa
J. Ananworanich, U. Siangphoe, A. Hill, P. Cardiello, W. Apateerapong, B. Hirschel, A. Mahanontharit, S. Ubolyam, D. Cooper, P. Phanuphak, K. Ruxrungtham (2005)
Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided Therapy Achieved Similar Virologic Suppression Compared With Patients on Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 39
J. Ananworanich, R. Nuesch, Michelle Braz, Ploechan Chetchotisakd, A. Vibhagool, Saijai Wicharuk, K. Ruxrungtham, H. Furrer, D. Cooper, B. Hirschel (2003)
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trialAIDS, 17
J. Fellay, B. Ledergerber, E. Bernasconi, H. Furrer, for Study (2001)
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort StudyThe Lancet, 358
P. Taffé, M. Rickenbach, B. Hirschel, M. Opravil, H. Furrer, P. Janin, F. Bugnon, B. Ledergerber, T. Wagels, P. Sudre (2002)
Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort studyAIDS, 16
The FOTO Study 48 week results : viral suppression can be maintained when antiretrovirals are taken five consecutive days on , and two days off each week
R. Nüesch (2006)
The Trivacan studyThe Lancet, 368
Impact of antiretroviral treatment interruption on morphologic changes: the Tibet Substudy
R. McClelland, J. Baeten, B. Richardson, L. Lavreys, S. Emery, K. Mandaliya, J. Ndinya‐Achola, J. Overbaugh (2006)
A Comparison of Genital HIV-1 Shedding and Sexual Risk Behavior Among Kenyan Women Based on Eligibility for Initiation of HAART According to WHO GuidelinesJAIDS Journal of Acquired Immune Deficiency Syndromes, 41
Jialun Zhou, N. Kumarasamy, R. Ditangco, A. Kamarulzaman, Christopher Lee, Patrick Li, N. Paton, P. Phanuphak, S. Pujari, A. Vibhagool, W. Wong, Fujie Zhang, J. Chuah, K. Frost, D. Cooper, M. Law (2005)
The TREAT Asia HIV Observational Database: Baseline and Retrospective DataJAIDS Journal of Acquired Immune Deficiency Syndromes, 38
S. Goldie, Y. Yazdanpanah, E. Losina, M. Weinstein, X. Anglaret, R. Walensky, H. Hsu, April Kimmel, C. Holmes, J. Kaplan, K. Freedberg (2006)
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.The New England journal of medicine, 355 11
A Thai cohort showing that grade III-IV laboratory toxicity is frequent but can be detected with very few tests
A pilot study to the larger Staccato trial. The CD4 cell count-guided arm was safe despite the fact that patients had had previous dual nucleoside therapy
Jon Cohen (2005)
A Step Toward Cheaper Anti-HIV TherapyScience, 307
H. Hatano, K. Miller, C. Yoder, J. Yanovski, N. Sebring, Elizabeth Jones, R. Davey (2000)
Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapyAIDS, 14
F. Palella, K. Delaney, A. Moorman, M. Loveless, J. Fuhrer, G. Satten, D. Aschman, S. Holmberg (1998)
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.The New England journal of medicine, 338 13
J. Ananworanich, A. Gayet-Ageron, Michelle Braz, W. Prasithsirikul, P. Chetchotisakd, S. Kiertiburanakul, Warangkana Munsakul, P. Raksakulkarn, Somboon Tansuphasawasdikul, S. Sirivichayakul, M. Cavassini, Urs Karrer, D. Genné, R. Nüesch, P. Vernazza, E. Bernasconi, Dominic Leduc, C. Satchell, S. Yerly, L. Perrin, A. Hill, T. Perneger, P. Phanuphak, H. Furrer, David Cooper, K. Ruxrungtham, B. Hirschel (2006)
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialThe Lancet, 368
A. Tuldrà, C. Fumaz, M. Ferrer, R. Paredes, J. Romeu, L. Ruíz, R. Bayés, B. Clotet (2001)
Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.AIDS, 15 14
T. Chun, A. Fauci (1999)
Latent reservoirs of HIV: obstacles to the eradication of virus.Proceedings of the National Academy of Sciences of the United States of America, 96 20
Structured treatment interruptions in HIV - infected patients with high CD 4 cell counts and virologic suppression : results of a prospective , randomized open - label trial ( Window - ANRS 106 )
A comprehensive review on many aspects of expanding HIV therapy worldwide
F. García, M. Plana, C. Vidal, A. Cruceta, W. O'brien, G. Pantaleo, T. Pumarola, T. Gallart, J. Miro, J. Gatell (1999)
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.AIDS, 13 11
B. Schwartländer, I. Grubb, J. Perriëns (2006)
The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing worldThe Lancet, 368
P. Braitstein, M. Brinkhof, F. Dabis, M. Schechter, A. Boulle, P. Miotti, R. Wood, C. Laurent, E. Sprinz, C. Seyler, D. Bangsberg, E. Balestre, J. Sterne, M. May, M. Egger (2006)
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countriesThe Lancet, 367
A description of what has been done so far to provide worldwide coverage of ART
A well designed multinational randomized controlled trial showing equal efficacy of CD4 cell count-guided STI on virological response and new AIDS
B. Hirschel (2001)
Planned interruptions of anti-HIV treatment.The Lancet. Infectious diseases, 1 1
M. Fischer, R. Hafner, Christine Schneider, A. Trkola, B. Joos, H. Joller, B. Hirschel, R. Weber, H. Günthard (2003)
HIV RNA in plasma rebounds within days during structured treatment interruptionsAIDS, 17
P. Bonfanti, L. Valsecchi, F. Parazzini, S. Carradori, L. Pusterla, P. Fortuna, L. Timillero, F. Alessi, G. Ghiselli, A. Gabbuti, E. Cintio, C. Martinelli, I. Faggion, S. Landonio, T. Quirino (2000)
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 23
A randomized controlled trial showing the failure of the week on/off strategy. The trial was a pilot to Staccato and patients included had had previous dual nucleoside therapy
M. Strain, H. Günthard, D. Havlir, C. Ignacio, Davey Smith, Andrew Leigh-Brown, T. Macaranas, R. Lam, O. Daly, M. Fischer, Milos Opravil, Herbert Levine, L. Bacheler, C. Spina, D. Richman, Joseph Wong (2003)
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistenceProceedings of the National Academy of Sciences of the United States of America, 100
E. Papasavvas, J. Kostman, K. Mounzer, R. Grant, R. Gross, C. Gallo, L. Azzoni, A. Foulkes, Brian Thiel, M. Pistilli, Agnieszka Mackiewicz, J. Shull, L. Montaner (2004)
Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 InfectionPLoS Medicine, 1
M. Dybul, T. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, B. Larder, R. Dewar, C. Fox, C. Hallahan, J. Justement, S. Migueles, J. Metcalf, R. Davey, M. Daucher, Punita Pandya, M. Baseler, D. Ward, A. Fauci (2001)
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parametersProceedings of the National Academy of Sciences of the United States of America, 98
J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, F. Lori (1999)
Control of HIV despite the discontinuation of antiretroviral therapy.The New England journal of medicine, 340 21
F. Wit, G. Weverling, J. Weel, S. Jurriaans, J. Lange (2002)
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.The Journal of infectious diseases, 186 1
L. Ruíz, G. Carcelain, J. Martinez-Picado, S. Frost, S. Marfil, R. Paredes, J. Romeu, Esther Ferrer, Kristina Morales-Lopetegi, B. Autran, B. Clotet (2001)
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infectionAIDS, 15
J. Montaner, R. Hogg, E. Wood, T. Kerr, M. Tyndall, Adrian Levy, P. Harrigan (2006)
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemicThe Lancet, 368
F. Lori, A. Foli, R. Maserati, E. Seminari, Jianqing Xu, L. Whitman, E. Ravot, F. Alberici, L. Lopalco, J. Lisziewicz (2002)
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responsesHIV Clinical Trials, 3
A merger of various cohort studies in industrialized and low-income countries
A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss, A. Monforte, B. Knysz, M. Dietrich, A. Phillips, J. Lundgren (2003)
Decline in the AIDS and death rates in the EuroSIDA study: an observational studyThe Lancet, 362
A. Hance, V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-vezinet, F. Clavel (2001)
Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral TherapyJournal of Virology, 75
B. Ledergerber, M. Egger, V. Erard, Reinhard Weber, B. Hirschel, H. Furrer, M. Battegay, P. Vernazza, E. Bernasconi, M. Opravil, D. Kaufmann, P. Sudre, P. Francioli, A. Telenti (1999)
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.JAMA, 282 23
J. Ananworanich, Z. Moor, U. Siangphoe, Jason Chan, P. Cardiello, C. Duncombe, P. Phanuphak, K. Ruxrungtham, J. Lange, D. Cooper (2005)
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsAIDS, 19
P. Cardiello, E. Hassink, J. Ananworanich, P. Srasuebkul, T. Samor, A. Mahanontharit, K. Ruxrungtham, B. Hirschel, J. Lange, P. Phanuphak, D. Cooper (2005)
UvA-DARE ( Digital Academic Repository ) A prospective , randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection
Effect of prolonged interruption of ART on mitochondrial toxicity
Y. Yazdanpanah (2004)
Costs associated with combination antiretroviral therapy in HIV-infected patients.The Journal of antimicrobial chemotherapy, 53 4
R. Nuesch, J. Ananworanich, S. Sirivichayakul, S. Ubolyam, U. Siangphoe, A. Hill, D. Cooper, J. Lange, P. Phanuphak, K. Ruxrungtham (2005)
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40 5
The effect of episodic CD4-guided antiretroviral therapy on quality of life: results of the quality of life substudy of SMART
C. Danel, R. Moh, A. Minga, A. Anzian, O. Ba-Gomis, C. Kanga, G. Nzunetu, D. Gabillard, F. Rouet, Souleymane Sorho, M. Chaix, S. Eholie, H. Menan, D. Sauvageot, E. Bissagnéné, R. Salamon, X. Anglaret (2006)
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trialThe Lancet, 367
and the Italian ISS-PART Clinical Centers. Factors predicting success and resistance in the STI arm of a randomized, controlled trial of continuous versus intermittent HAART
R. Miller, D. Daniels
Enhanced risk of HIV sexual transmission during structured treatment interruption
P. Weidle, S. Malamba, R. Mwebaze, C. Sozi, Gideon Rukundo, R. Downing, D. Hanson, Dorothy Ochola, P. Mugyenyi, J. Mermin, B. Samb, E. Lackritz (2002)
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistanceThe Lancet, 360
J. Siliciano, Joleen Kajdas, D. Finzi, T. Quinn, K. Chadwick, J. Margolick, C. Kovacs, S. Gange, R. Siliciano (2003)
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cellsNature Medicine, 9
P. Brown (2000)
Cheaper AIDS drugs due for Third World…Nature, 405
Felipe García, M. Plana, M. Arnedo, G. Ortiz, J. Miro, L. Lopalco, F. Lori, T. Pumarola, T. Gallart, J. Gatell (2003)
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized studyAIDS, 17
M. Silverberg, M. Gore, A. French, M. Gandhi, M. Glesby, A. Kovacs, T. Wilson, M. Young, S. Gange (2004)
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39 5
J. Hakim (2006)
A structured treatment interruption (STI) strategy of 12 week cycles on and off DART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomization within the DART trial.
C. Duncombe, S. Kerr, K. Ruxrungtham, G. Dore, M. Law, S. Emery, J. Lange, P. Phanuphak, D. Cooper (2005)
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingAIDS, 19
Benson Ca (2001)
Structured treatment interruption in HIV infection.The AIDS reader, 11 2
Episodic CD 4 - guided use of antiretroviral therapy is inferior to continuous therapy : results of the SMART study
R. Hogg, A. Weber, K. Craib, A. Anis, M. O'Shaughnessy, M. Schechter, J. Montaner (1998)
One world, one hope: the cost of providing antiretroviral therapy to all nationsAIDS, 12
A thorough cost-effectiveness analysis of ART in settings with limited resources
Colette Smith, C. Sabin, F. Lampe, S. Shah, M. Tyrer, M. Youle, I. Cropley, M. Johnson, A. Phillips (2005)
The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral RegimensAntiviral Therapy, 10
N. Friis‐Møller, R. Weber, P. Reiss, R. Thiébaut, O. Kirk, A. Monforte, C. Pradier, L. Morfeldt, S. Mateu, M. Law, W. El-Sadr, S. Wit, C. Sabin, A. Phillips, J. Lundgren (2003)
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 17
Thomas Alexander, G. Ortiz, M. Wellons, Andrew Allen, Edward Grace, B. Schweighardt, J. Brancato, J. Sandberg, S. Furlan, G. Miralles, D. Nixon, J. Bartlett (2003)
Changes in CD4+ T-Cell Differentiation Phenotype During Structured Treatment Interruption in Patients With Chronic HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 34
R. Rij, R. Praag, J. Prins, R. Rientsma, S. Jurriaans, J. Lange, H. Schuitemaker (2002)
Persistence of Viral HLA-DR- CD4 T-Cell Reservoir during Prolonged Treatment of HIV-1 Infection with a Five-Drug RegimenAntiviral Therapy, 7
L. Ruíz, R. Paredes, G. Gómez, J. Romeu, P. Domingo, N. Pérez-Álvarez, G. Tambussi, J. Llibre, J. Martinez-Picado, F. Vidal, C. Fumaz, B. Clotet (2007)
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patientsAIDS, 21
S. Lawn, L. Myer, G. Harling, C. Orrell, L. Bekker, R. Wood (2006)
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 6
F. Lori, R. Maserati, A. Foli, E. Seminari, J. Timpone, J. Lisziewicz (2000)
Structured treatment interruptions to control HIV-1 infectionThe Lancet, 355
F. Maggiolo, D. Ripamonti, G. Gregis, G. Quinzan, A. Callegaro, F. Suter (2004)
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trialAIDS, 18
Treatment interruption for convenience, cost cutting and toxicity sparing a b Reto Nu ¨ esch and Bernhard Hirschel Purpose of review Introduction Scheduled treatment interruption appears to be an Despite the highly beneficial effect of antiretroviral attractive alternative to continuous treatment in reducing therapy (ART) on the mortality and morbidity of HIV side effects and costs and increasing comfort and quality of infection [1 – 5], its long-term success is challenged by life by reducing overall drug exposure. The question is the many problems inherent in life-long therapy. The whether such an interruption is safe. The development of perspective of never-ending pill ingestion is dispiriting resistance, treatment failure, and the occurrence of to many patients, leading to treatment fatigue with possible diseases induced by decreasing CD4 cell counts or negative effects on adherence [6 – 8]. Drug toxicity is a well virological rebound are matters of concern. recognized problem in industrialized and developing Recent findings countries alike [9 – 15,16 ], and the costs of treating millions Fixed-cycle scheduled treatment interruption and CD4 cell- are challenging healthcare systems worldwide. These guided treatment interruption have been evaluated in issues will become ever more urgent with increased access randomized controlled trials.
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Jan 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.